WCLC 2023 ハイライト

最初から再生

WCLC Highlights 2023

Forward-Looking Statements

Agenda

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Efficacious and Tolerable New Therapies Are Needed for EGFR-Mutated NSCLC After Failure of an EGFR TKI and Platinum-Based Chemotherapy

Patritumab Deruxtecan (HER3-DXd)

HERTHENA-Lung01 Study Design

Patients Were Heavily Pretreated and Had Adverse Prognostic Characteristics

Clinically Meaningful Efficacy Was Observed in the Overall Population and Across Subgroups

Tumor Reduction Across Diverse Mechanisms of EGFR TKI Resistance

Tumor Reduction Across Diverse Mechanisms of EGFR TKI Resistance

Efficacy Observed Across a Broad Range of Pretreatment Tumor HER3 Membrane Expression Levels

Intracranial Responses (by CNS BICR) Observed With HER3-DXd

The Safety Profile of HER3-DXd Was Manageable and Tolerable

Conclusions

Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/Metastatic NSCLC: Initial Results from the Phase 1b TROPION-Lung04 Study

Background

TROPION-Lung04 Study Design Phase 1b, multicenter, open-label, dose escalation/confirmation and expansion study

Baseline Characteristics and Patient Disposition

Safety Summary

TEAEs in 15% of Patients

Antitumor Activity

Best Change in Sum of Diameters of Target Lesions

Depth and Durability of Response

Conclusions

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

DESTINY-Lung02 Blinded, randomized, multicenter, international, noncomparative, phase 2 trial (NCT04644237)

Baseline Characteristics and Efficacy Summary

Best Percentage Change in Tumor Size by BICR With T-DXd 5.4 mg/kg (N = 102)

Overall Safety Summary

Conclusions

Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1/2 study

Ifinatamab Deruxtecan (I-DXd; DS-7300) Was Designed With 7 Key Attributes

DS7300-A-J101 Study Design (NCT04145622)

Patient Demographics and Baseline Characteristics

Antitumor Activity

Progression-Free and Overall Survival

Safety Summary

Most Common ( 10%) All-Grade TEAEs Regardless of Causality

B7-H3 Correlative Results for SCLC Cohorta

Conclusions

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

@